Skip to content
Screener

Interest Income at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$5M-16.7%
uniQure logo
uniQureQURE
$5.05M+43.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$8.49M+29.7%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$1.32M+41.5%

Segments

By segment

See full
Therapeutics Segment$2.99M-72.4%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Intangible asset amortization750750
Total operating expenses134,145134,963271,502280,543
Loss from operations(130,541)(134,963)(267,898)(280,543)
Interest and other income, net2,98810,84411,89823,454
Net loss$(127,553)$(124,119)$(256,000)$(257,089)
Other comprehensive loss:
Net unrealized loss on marketable securities, net of tax(1,287)(1,098)(2,651)(1,081)
Comprehensive loss$(128,840)$(125,217)$(258,651)$(258,170)

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s interest income?
Denali Therapeutics Inc. (DNLI) reported interest income of $2.99M in Q2 2026.
How has Denali Therapeutics Inc.'s interest income changed year-over-year?
Denali Therapeutics Inc.'s interest income decreased by 72.4% year-over-year, from $10.84M to $2.99M.
What is the long-term trend for Denali Therapeutics Inc.'s interest income?
Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s interest income has grown at a 42.7% compound annual growth rate (CAGR), from $14.77M to $42.9M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Denali Therapeutics Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude